Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer

Kanayama, Hiro‐omi; Yokota, K; Kurokawa, Yasushi; Murakami, Y.; Nishitani, Masaaki; Kagawa, Shunsuke

doi:10.1002/(sici)1097-0142(19980401)82:7<1359::aid-cncr20>3.0.co;2-4

Cited by 170 publications

(77 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Biochemical research has revealed a complex biphasic contribution of TIMP-2 to the modulation of MMP-2-mediated matrix lysis: at low concentrations, TIMP-2 participates in the activation of proMMP-2 by MT1-MMP, whereas high concentrations of TIMP-2 completely block the activities of both MMP-2 and MT1-MMP (Kinoshita et al, 1998;Kurschat et al, 1999). Clinical studies have indicated that increased levels of MMPs, in particular MMP-2, MMP-9, and MT1-MMP, are correlated with a poor prognostic in cancer patients (Kanayama et al, 1998;Thomas et al, 2000).…”

Section: Introductionmentioning

confidence: 63%

AdTIMP-2 Inhibits Tumor Growth, Angiogenesis, and Metastasis, and Prolongs Survival in Mice

Lindenmeyer

Grenet

et al. 2001

Human Gene Therapy

View full text Add to dashboard Cite

TIMP-2 is a natural matrix metalloproteinase (MMP) inhibitor that prevents the degradation of extracellular matrix proteins. It abolishes the hydrolytic activity of all activated members of the metalloproteinase family and in particular that of MT1-MMP, MMP-2, and MMP-9, which are selective for type IV collagenolysis. Since MMPs have been implicated in both cancer progression and angiogenesis, we generated a recombinant adenovirus to deliver human TIMP-2 (AdTIMP-2) and evaluated its anticancer efficiency in three murine models. Our results demonstrated that overexpression in vitro of TIMP-2 inhibited the invasion of both tumor and endothelial cells without affecting cell proliferation. Its in vivo efficiency has been evaluated in murine lung cancer LLC, and colon cancer C51 in syngeneic mice as well as in human breast cancer MDA-MB231 in athymic mice. Preinfection of tumor cells by AdTIMP-2 resulted in an inhibition of tumor establishment in more than 50% of mice in LLC and C51 models and in 100% mice in the MDA-MB231 model. A single local injection of AdTIMP-2 into preestablished tumors of these three types significantly reduced tumor growth rates by 60--80% and tumor-associated angiogenesis index by 25--75%. Lung metastasis of LLC tumor was inhibited by >90%. In addition, AdTIMP-2-treated mice showed a significantly prolonged survival in all the cancer models tested. These data demonstrate the potential of adenovirus-mediated TIMP-2 therapy in cancer treatment.

show abstract

Section: Introductionmentioning

confidence: 63%

AdTIMP-2 Inhibits Tumor Growth, Angiogenesis, and Metastasis, and Prolongs Survival in Mice

Lindenmeyer

Grenet

et al. 2001

Human Gene Therapy

View full text Add to dashboard Cite

show abstract

“…MMP-2 (gelatinase), in particular, degrades the extracellular matrix and is involved in tumor infiltration and tumor-induced neovascularization (2)(3)(4). Numerous clinical studies show a clear correlation between MMP-2 expression and poor outcome of disease (3,(5)(6)(7). This correlation has been the major impetus to develop a number of MMP inhibitors, some of them currently in phase III clinical trials (8 -15).…”

mentioning

confidence: 99%

Optical Imaging of Matrix Metalloproteinase–2 Activity in Tumors: Feasibility Study in a Mouse Model

Bremer¹,

Bredow²,

Mahmood³

et al. 2001

Radiology

241

184

View full text Add to dashboard Cite

show abstract

“…Für CK20 wurde eine Rolle in der Differenzierung von Papillomen und Karzinomen und auch eine prognostische Bedeutung beschrieben [32]. Metallomatrixproteasen degradieren extrazelluläre Matrix und sind daher für die Invasionsfähigkeit einer Zelle bedeutsam -beim Harnblasenkarzinom fand sich für die Subgruppen 2 und 9 eine allerdings nicht unabhängige Korrelation mit fortgeschrittenen Tumoren und einer Progressionsneigung [33].…”

Section: Invasionsmarker: Die Matrixproteine Ck20 Mmp E-cadherin Punclassified

Nutzung von Markersystemen in der Behandlung des Harnblasenkarzinoms

Burger

Dorp

2011

Urologe

View full text Add to dashboard Cite

Accepted prognostic factors for urothelial carcinomas of the bladder are tumor grade, T category, and in cases of muscle invasive carcinoma lymph node status. These morphological criteria correlate in general with the clinical course of patients suffering from bladder cancer. Beside histomorphological criteria the search for prognostic markers independent of histological evaluation seems to be important as the clinical course of bladder cancer patients can be very heterogeneous. For this purpose we reviewed the current literature and focussed on additional molecular markers with prognostic relevance.

show abstract

Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer

Abstract: MMP-2 and TIMP-2 are believed to contribute to the invasive properties of bladder carcinoma. The authors report that expression of MMP-2, TIMP-2, and MT1-MMP are useful prognostic indicators in patients with bladder carcinoma and may be helpful in designing treatment protocols.

Cited by 170 publications

References 21 publications

AdTIMP-2 Inhibits Tumor Growth, Angiogenesis, and Metastasis, and Prolongs Survival in Mice

AdTIMP-2 Inhibits Tumor Growth, Angiogenesis, and Metastasis, and Prolongs Survival in Mice

Optical Imaging of Matrix Metalloproteinase–2 Activity in Tumors: Feasibility Study in a Mouse Model

Nutzung von Markersystemen in der Behandlung des Harnblasenkarzinoms

Contact Info

Product

Resources

About